SOAT1 and graft versus host disease: Since the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway is crucial for the activation of immune cells and tissue inflammation during GvHD, ruxolitinib, an orally applied JAK 1/2 inhibitor, has been explored for the treatment of GvHD [13, 14].